oncbrain — oncology meeting digest

PrTK03 (aglatimagene besadenovec + EBRT)

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer. Eligible: Intermediate/high-risk localized prostate cancer, ECOG 0–2, planning definitive

AREST

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] 3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS. Eligible: pT1-2 pN0 OSCC, intermediate-risk (DOI/PNI/LVE/poor diff), post-curative surgery

mRCAT-III

Tue, 02 Jun 2026 00:00:00 GMT

[Early signal] pCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC. Eligible: pMMR/MSS LARC, cT3-4N0/+M0, tumor ≤10cm from anal verge, no positive lateral LN

ES-SCLC Concurrent TRT + Chemoimmunotherapy (LBA8005)

Tue, 02 Jun 2026 00:00:00 GMT

[Confirmatory] mOS 10.0 vs 11.8mo, HR 1.14, p=0.40: concurrent TRT adds no OS benefit to chemoIO in ES-SCLC. Eligible: ES-SCLC, treatment-naïve, ECOG 0-1, measurable thoracic lesion

DeLLphi-304 (tarlatamab CNS outcomes)

Mon, 01 Jun 2026 00:00:00 GMT

[Caveats dominate] CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC. Eligible: 2L ES-SCLC; brain mets subgroup ≥1 BM at baseline, >70% prior CNS treatment

PROTEUS

Sun, 31 May 2026 00:00:00 GMT

[Caveats dominate] 53.0% (APA) and 60.7% (ADT) of MFS events PSMA PET-detected; APA+ADT vs ADT benefit in BCR prostate hotly contested. Eligible: Biochemically recurrent prostate cancer, post-radical prostatectomy

ENZARAD

Sun, 31 May 2026 00:00:00 GMT

[Confirmatory] MFS HR 0.88 (p=0.34), OS HR 0.87 (p=0.40); enzalutamide added to RT+2y ADT did not improve outcomes in high-risk localized PCa. Eligible: High-risk localized PCa (Gleason 8-10, T3-4, or N1, or PSA ≥20 ng/mL), suitable

RASolute 302

Sun, 31 May 2026 00:00:00 GMT

[Practice-changing] Daraxonrasib vs IC chemo in 2L RAS G12 mPDAC: mOS 13.2 vs 6.6 mo, HR 0.40 (0.30-0.54), p<0.001. Eligible: Prev-treated metastatic PDAC, RAS G12 mutation, ≥1 prior systemic line

ENZAMET + Decipher Biomarker Analysis

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] Decipher >0.85 identifies mHSPC pts with OS benefit from docetaxel intensification; IPTW interaction p=0.04, HR 0.75 (0.43-1.33). Eligible: mHSPC, ADT + enzalutamide backbone, tumor tissue available for Decipher testing

TALAPRO-3

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] 3yr rPFS 77% vs 56% (HR 0.48, p<0.001) favoring talazoparib+enza+ADT in HRR-deficient mHSPC. Eligible: HRR-deficient metastatic hormone-sensitive prostate cancer

OptiTROP-Lung05

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] mPFS NR vs 5.7mo, HR 0.35 (0.26-0.47), p<0.0001 favoring sac-TMT + pembro in 1L PD-L1+ NSCLC. Eligible: Stage IIIB-IV NSCLC, PD-L1 TPS ≥1%, no EGFR/ALK, treatment-naive, ECOG 0-1

Neo-CRAG

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] Adding neoadj CRT to peri-op XELOX: mDFS 52.7 vs 24.4 mo, mOS 67.5 vs 37.6 mo in high-risk LAGC. Eligible: Locally advanced gastric/GEJ adenocarcinoma (cT3N2+, T4), peri-op XELOX eligible

Wait or Treat — NCT05236946 (Upfront vs Delayed Brain RT in Oncogene-mutated NSCLC)

Fri, 29 May 2026 00:00:00 GMT

[Challenges SOC] Upfront brain RT halves icPD (HR 0.35, p<0.001) but OS numerically favors delayed (HR 1.45, 2yr 60% vs 48%) in EGFR/ALK+ mNSCLC. Eligible: Metastatic NSCLC, EGFR or ALK mutant, completely asymptomatic BM, ECOG 0-2

SENOMAC

Wed, 27 May 2026 00:00:00 GMT

[Confirmatory] 5yr RFS 89.7% vs 88.7%, HR 0.89: SNB alone noninferior to ALND in cN0 breast cancer with 1-2 SN macrometastases. Eligible: cN0 breast cancer, T1-T3, 1-2 SN macrometastases, BCT or mastectomy

SWOG/NRG S1914

Tue, 26 May 2026 00:00:00 GMT

[Confirmatory] No OS benefit from adding atezolizumab to SBRT (HR 1.15, p=0.63); closed for futility; G≥3 AEs 12% vs 2%. Eligible: Inoperable early-stage NSCLC T1-3N0M0 ≤7cm, ≥1 recurrence risk factor

Bladder Adjuvant Radiotherapy

Thu, 21 May 2026 00:00:00 GMT

[Early signal] 2-yr LRFS 87.1% vs 76.0% (HR 0.43, p=0.04) favoring adj pelvic IMRT post-cystectomy in high-risk MIBC; DFS/OS NS. Eligible: High-risk urothelial MIBC post-RC (pT3-4, pN+, margin+, or ≤10 nodes), periopera

EORTC 22922/10925

Thu, 21 May 2026 00:00:00 GMT

[Challenges SOC] 20yr OS HR 1.00 (null): BC mortality reduced HR 0.82 but non-BC deaths increased HR 1.26, offsetting benefit. Eligible: Stage I-III breast, node-positive or central/medial tumor, median age 54, post-s

LS-SCLC 54 Gy Hyperfractionated RT

Wed, 20 May 2026 00:00:00 GMT

[Challenges SOC] mOS 60.7 vs 39.5mo (HR 0.55, p=0.003) favoring 54 Gy hyperfractionated RT in LS-SCLC; no added toxicity. Eligible: LS-SCLC, ECOG 0–1, age 18–70, chemo-naive or ≤1 prior platinum-etoposide cycle

PEACE 2

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] Pelvic RT did not improve cPFS vs prostate-only RT in VHR localized prostate cancer (HR 0.81, p=0.088). Eligible: VHR localized prostate (≥2: Gleason ≥8, T3-T4, PSA ≥20), N0M0 on conventional im

HEAT Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] SBRT 5 fx non-inferior to EHRT for BF (7% vs 7.4%, p-noninferiority=0.007 at 4.25y) in low-int risk PCa; interim data. Eligible: Low-intermediate risk localized PCa, IPSS <12, ADT-eligible

TORPEdO (CRUK/18/010)

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] IMPT showed no HR-QoL benefit vs IMRT at 12 months in OPSCC; UW-QoL scores similar across arms to 24 months. Eligible: Oropharyngeal SCC requiring definitive concurrent CRT with bilateral neck treatm

NRG/RTOG 1005

Mon, 18 May 2026 00:00:00 GMT

[Practice-changing] 7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04); concurrent boost noninferior, reducing treatment to 15 fractions. Eligible: Post-lumpectomy high-risk early breast: grade 3, ER-neg, LVI, or close margins

APBI-IMRT Florence

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 15-yr IBTR 7.7% vs 4.2% (HR 1.57, p=0.17); no locoregional control, BCSS, or OS difference confirms APBI de-escalation. Eligible: Early BC post-BCS, pT <25mm, FSM ≥5mm, age >40

DBCG HYPO

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 10-yr G2-3 induration HR 0.76 (19.5% vs 24.7%) favoring 40Gy/15fr; OS and locoregional outcomes equivalent at 12.8yr median f/u. Eligible: Node-negative early breast cancer or DCIS, adjuvant whole-breast RT

IMPORT HIGH

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 48Gy SIB: 10-yr IBTR 3.7% vs 3.5% sequential boost, non-inferior; further escalation to 53Gy not beneficial (5.5%). Eligible: Invasive early BC (pT1-3, pN0-N3a, M0) post-BCS requiring tumour bed boost RT

EORTC IM-MS (22922/10925)

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 20-yr OS null (HR 1.00, p=0.967); BCM benefit offset by non-BCM excess; pN0: no benefit. Eligible: Stage I-III BC, node-positive or pN0, adjuvant IM-MS RT decision

DBCG RT Natural

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 9.8% 4-yr LR without PBI vs 1.5% with PBI in pT1N0 low-risk elderly breast conservation; stopped early per pre-specified threshold. Eligible: ≥60y, pT1N0, ER+ ≥10%, HER2-normal, grade 1-2, unifocal post-lumpectomy

HypoG-01

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] LRR 16% of 118 events; failure patterns comparable between 40 Gy/15fx and 50 Gy/25fx; most in-volume per ESTRO guidelines. Eligible: Early-stage breast cancer, adjuvant hypofractionated RT

PRIME

Sun, 17 May 2026 00:00:00 GMT

[Early signal] SBRT 5fx with pelvic RT: G3+ toxicity <1%, comparable early BFFS to moderate hypo (N~434); mature 4-5yr endpoint pending. Eligible: High-risk, very high-risk, or node-positive non-metastatic prostate cancer

PIVOTALboost

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Late G2+ bowel 6.5-8.7%, bladder 16.5-24.1% at 2yr, no increase with focal boost or pelvic node RT vs prostate-only (N=1465). Eligible: High-risk localised prostate cancer, moderately fractionated 20-fraction RT

PACE-NODES

Sun, 17 May 2026 00:00:00 GMT

[Early signal] PPN-SBRT increases G≥2 GI toxicity (28% vs 21%) vs prostate-only SBRT; symptoms resolved by 12wk; GU toxicity equivalent; efficacy endpoint pending. Eligible: High-risk localised prostate (T3a-T4, Gleason 8-10, or PSA >20), planned ADT 12-

PEACE-2

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Pelvic RT adds no significant cPFS benefit over prostate-only RT in very high-risk PCa with 3yr ADT (HR 0.81, p=0.088) at interim analysis. Eligible: Very high-risk localized prostate Ca (≥2 of Gleason ≥8, T3-T4, PSA ≥20), N0M0